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Xenobiotic metabolising N-acetyltransferases (NATs) perform biotransformation of drugs and 
carcinogens. Human NAT1 is associated with endogenous metabolic pathways of cells and is a candidate 
drug target for cancer. Human NAT2 is a well-characterised polymorphic xenobiotic metabolising 
enzyme, modulating susceptibility to drug-induced toxicity. Human NATs are difficult to express 
to high purification yields, complicating large-scale production for high-throughput screens or use 
in sophisticated enzymology assays and crystallography. We undertake comparative functional 
investigation of the NAT homologues of ten non-human primates, to characterise their properties and 
evaluate their suitability as models of human NATs. Considering the amount of generated recombinant 
protein, the enzymatic activity and thermal stability, the NAT homologues of non-human primates are 
demonstrated to be a much more effective resource for in vitro studies compared with human NATs. 
Certain NAT homologues are proposed as better models, such as the NAT1 of macaques Macaca mulatta 
and M. sylvanus, the NAT2 of Erythrocebus patas, and both NAT proteins of the gibbon Nomascus 
gabriellae which show highest homology to human NATs. This comparative investigation will facilitate 
in vitro screens towards discovery and optimisation of candidate pharmaceutical compounds for human 
NAT isoenzymes, while enabling better understanding of NAT function and evolution in primates.
The xenobiotic metabolising N-acetyltransferase (NAT) enzymes are involved in the biotransformation of drugs 
and carcinogens. NATs are conjugation enzymes typically employing acetyl-coenzyme A (CoA) as donor sub-
strate to perform N-acetylation of an arylamine or arylhydrazine acceptor substrate during a two-step ping-pong 
Bi-Bi reaction catalysed by a triad of cysteine, histidine and aspartate residues1,2. The diversity of NAT homo-
logues is extensive, as evidenced through previous comparative genomic surveys and phylogenetic analyses across 
a broad taxonomic range of prokaryotes and eukaryotes3–6. The phylogeny of NAT homologues in both simple 
(fungi) and complex (vertebrates) eukaryotes suggests a dynamic birth-and-death evolutionary pattern, where 
multiple lineage-specific gene duplications and losses, combined with selection-driven sequence divergence, have 
promoted functional diversification of NAT enzymes, presumably allowing rapid adaptation to variable xenobi-
otic environments5,6. Enzymatic and structure-function investigations, particularly with microbial NATs, support 
this model, as they reveal variability even in key catalytic components in certain organisms7–10.
In primates, our phylogenetic analysis6 predicted an initial duplication of the ancestral NAT gene in the com-
mon ancestor of Simiiformes, generating NAT1 and a second NAT gene which subsequently duplicated in the 
common ancestor of Catarrhini (Old World monkeys and apes, including human) to give rise to NAT2 and the 
pseudogene NATP. Platyrrhini (New World monkeys) appear to lack the third NAT locus, while other independ-
ent duplication events may have occurred in the lower primate lineages of Strepsirrhini and Tarsiiformes. NAT1 
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evolution in primates appears to be primarily subject to purifying selection, potentially maintaining some endog-
enous metabolic function. NAT2 evolution is more likely driven by diversifying selection favouring variability 
in amino acid sequence, possibly as adaptation to changing xenobiotic exposures. These observations are sup-
ported by population genetic studies of human NAT genes, predicting that changing selective pressures on NAT2, 
rather than NAT1, may have favoured expansion of the slow acetylator genotype/phenotype after the agricul-
tural revolution of the Neolithic period11–16. Human NAT1 gene expression begins very early in embryogenesis17  
and is evident in a range of tissues, driven by a housekeeping promoter18,19. By contrast, human NAT2 shows a 
more restricted expression pattern consistent with its well-established role as hepatic xenobiotic metabolising 
enzyme20. Polymorphisms are also more common and their effects on xenobiotic acetylation more apparent for 
human NAT2 compared with NAT1 gene21.
Expanding previous in silico phylogenetic analyses of primate NATs6, we undertook a comparative functional 
investigation of the NAT1 and NAT2 homologues of eleven primate species, including human. The recombinant 
NAT proteins of non-human primates are proposed as models of their human counterparts, particularly for in vitro 
screens towards the discovery and optimisation of candidate pharmaceutical compounds.
Results and Discussion
Primate NAT genes and proteins. We have previously reported6 sequencing of NAT genes from the 
non-human primates Sapajus apella (a New World monkey from South America), Allenopithecus nigroviridis, 
Cercopithecus diana, Chlorocebus tantalus, Erythrocebus patas, Macaca sylvanus and Mandrillus sphinx (Old 
World monkeys from across Africa), Macaca mulatta and Trachypithecus cristatus (Old World monkeys from 
South Asia), and Nomascus gabriellae (an ape from Southeast Asia). Of those ten species, the gibbon N. gabriellae 
is taxonomically more closely related to Homo sapiens (human). The corresponding consensus classification 
of these primates is shown in Supplementary Fig. S1, with additional information provided in Supplementary 
Table S1.
Suitable species-specific mnemonics were assigned to symbols of annotated NAT genes (Table 1), according to 
current consensus nomenclature rules22, and complete coding sequences of 873 bp were cloned in expression vec-
tor. The translated 290 amino acid NAT sequences were highly conserved; identity ranged from 94.16 to 100% for 
NAT1 and from 85.57 to 99.66% for NAT2 sequences, with higher variability observed among NAT2 than among 
NAT1 homologues (Supplementary Fig. S2 and Supplementary Table S2). The phylogeny of protein sequences 
was in line with the species taxonomy of Supplementary Fig. S1, but the NAT1 and NAT2 homologues clustered 
as separate groups, supporting two distinct lineages of NAT orthologues in the simians (Supplementary Fig. S3). 
These observations are consistent with our earlier evolutionary studies of primate NATs6.
Nine NAT1 homologues were expressed in recombinant form, representing all eleven primate species in this 
study, including human. NAT1 protein sequences were identical between C. tantalus and E. patas, as well as 
between M. mulatta and M. sylvanus. Expression of nine NAT2 homologues was also performed, representing 
all species except A. nigroviridis and S. apella (Table 1). Using a standard expression and affinity chromatography 
purification method, the 18 recombinant proteins were recovered at variable levels of yield and purity (Fig. 1). 
Expression of NAT homologues of non-human primates was consistently higher compared with (HUMAN)
NAT1 and (HUMAN)NAT2 proteins, which were generated in very low amounts. Overall, the expression of 
non-human NAT1 homologues was considerably higher compared with non-human NAT2 homologues, ena-
bling more effective purification of the former.
Unlike the (HUMAN)NAT proteins, further chromatographic purification was possible for the gibbon 
(NOMGA)NAT1 and (NOMGA)NAT2, as well as for other readily expressed NAT homologues of non-human 
primates. Under the gel filtration conditions used, the NAT proteins were recovered as monomers with the 
expected molecular mass (Supplementary Fig. S4). Purified proteins (ALLNI)NAT1, (NOMGA)NAT1 and 
(TRACR)NAT1 (Supplementary Fig. S5) were further selected for crystallisation screens with commercial panels 
(Morpheus®, JCSG plusTM, MidasTM, Structure Screen 1 & 2 HT-96 and Wizard, all from Molecular Dimensions), 
using the facilities of the Department of Biochemistry at Oxford University. Although these initial crystallisation 
attempts did not provide any useful crystals, the production of purified NAT proteins (3–10 mg per litre of culture) 
from various non-human primates is encouraging, laying the groundwork for future screens.
Previous studies have shown that human NATs are very difficult to express to high purification yields in 
Escherichia coli, complicating their large-scale production for high-throughput screens of chemical libraries, or for 
use in sophisticated crystallographic and enzymological investigations. For crystallisation, Wu and colleagues23 
generated recombinant (HUMAN)NAT1 and (HUMAN)NAT2 proteins to purification yields of 1.6 and 0.5 mg 
per litre of bacterial culture, respectively (http://www.thesgc.org/structures/2IJA; http://www.thesgc.org/struc-
tures/2PQT; http://www.thesgc.org/structures/2PFR). Another group has also been successful in producing fully 
purified (HUMAN)NAT1 and (HUMAN)NAT2 proteins to high yields (4 and 1.4 mg/L, respectively), and these 
preparations have been used to advance knowledge of NAT enzymatic catalysis and inhibition24–27. However, the 
bulk of studies measuring recombinant activity of human NAT isoenzymes have employed either crude lysates 
(of bacterial, yeast or mammalian cells) or partially purified proteins in low yields. In many instances, enzymatic 
activity of human NATs and their polymorphic variants has been measured in preparations where recombinant 
protein is detectable only by Western blot28–40.
The recombinant NAT proteins of laboratory rodents have been popular substitutes of human NATs in studies 
of catalytic function or in vitro screens for pharmaceutical compounds39–47. However, compared with the NAT 
proteins of non-human primates, the rodent homologues are less suitable models, given their considerably lower 
identity to human NATs (Supplementary Table S2). Moreover, although human NAT1 and rodent Nat2 genes are 
orthologous (i.e. they share common phylogenetic ancestry and function), this is not true for human NAT2 and 
rodent Nat1 genes which have derived through independent genomic duplications occuring after the divergence 
of rodents and primates6,44,47.
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The advantages of expressing recombinant NAT1 and NAT2 proteins of non-human primates, for use as in 
vitro models of their human homologues, are obvious. In particular, the gibbon N. gabriellae could serve as a con-
venient model, since it was possible to efficiently express and purify its NAT isoenzymes (Supplementary Fig. S4 
and Supplementary Fig. S5). Sequence identity is 95.88% between (HUMAN)NAT1 and (NOMGA)NAT1, as well 
as between (HUMAN)NAT2 and (NOMGA)NAT2, which corresponds to a difference of only 12 amino acids per 
each pair of homologues (Supplementary Fig. S2 and Supplementary Table S2).
Enzymatic activities of primate NAT proteins. All recombinant NAT proteins were assayed for enzymatic 
activity against the (HUMAN)NAT1 selective substrate p-aminobenzoate (PABA) and the (HUMAN)NAT2 
selective substrates procainamide (PA, an antiarrhythmic arylamine) and isoniazid (INH, an anti-tubercular aryl-
hydrazine). Assays were also performed with the less selective arylamine substrates 5-aminosalicylate (5AS) and 
p-anisidine (PANS)35. Overall, the NAT isoenzymes of non-human primates demonstrated the expected substrate 
specificity pattern, but enzyme activities varied considerably among species (Fig. 2).
The specific activities measured for (HUMAN)NAT1 and (HUMAN)NAT2 were lowest, even with selective 
substrates, and this was possibly due to the poor quality of recombinant preparations generated for those two 
proteins under the standard expression/purification conditions used (Fig. 1). However, the gibbon (NOMGA)
NAT1 and (NOMGA)NAT2 isoenzymes provided relatively low specific activities too, despite their more robust 
recombinant expression and purification. Compared with other primates, NAT enzymatic activities may be lower 
Scientific name (synonym)a Common namea
Taxon 
mnemonica
Taxon 
IDa Geneb GenBank IDb
Amplification 
primersc
Allenopithecus nigroviridis Allen’s swamp monkey ALLNI 54135 NAT1 KU640972 #1 and #2
Cercopithecus diana Diana monkey CERDI 36224
NAT1 KU640973 #1 and #2
NAT2 KU640982 #1 and #3
Chlorocebus tantalus (Cercopithecus tantalus) Tantalus monkey CHLTN 60712
NAT1 KU640974 #6 and #7
NAT2 KU640983 #1 and #3
Erythrocebus patas (Cercopithecus patas) Red guenon ERYPA 9538
NAT1 KU640975 #6 and #7
NAT2 KU640984 #1 and #3
Homo sapiens Human HUMAN 9606
NAT1 X17059 (allele NAT1*4) #1 and #2
NAT2 X14672 (allele NAT2*4) Clone available
Macaca mulatta Rhesus macaque MACMU 9544
NAT1 KU640969 #1 and #2
NAT2 AJ504440 (allele NAT2*1) Clone available
Macaca sylvanus Barbary macaque MACSY 9546
NAT1 KU640970 #1 and #2
NAT2 KU640978 #1 and #3
Mandrillus sphinx (Papio sphinx) Mandrill MANSP 9561
NAT1 KU640971 #1 and #2
NAT2 KU640980 #1 and #3
Nomascus gabriellae Red-cheeked gibbon NOMGA 61852
NAT1 KU640967 #1 and #2
NAT2 KU640985 #1 and #4
Sapajus paella (Cebus apella) Brown-capped capuchin SAPAP 9515 NAT1 KU640966 #1 and #2
Trachypithecus cristatus (Presbytis cristata) Silvered leaf-monkey TRACR 122765
NAT1 KU640968 #1 and #2
NAT2 KU640977 #1 and #5
Table 1. Description of NAT gene constructs and their primate species of origin. aThe current scientific names 
of species with synonymous names in parentheses (first column) and a common name (second column), 
are from the UniProt Taxonomy database (http://www.uniprot.org/taxonomy/). Official taxon mnemonics 
(third column) and taxon identification numbers (fourth column) are from the same source. According to 
current consensus nomenclature (http://nat.mbg.duth.gr/), taxon mnemonics are attached to the symbols 
of NAT genes to identify their specific organism of origin22. bAll NAT gene annotations (fifth column) are as 
first described by6, except for the NAT2 gene of M. mulatta60, and the NAT1 and NAT2 genes of H. sapiens66. 
The recombinant proteins expressed in this study were as predicted by translation of the nucleotide sequences 
for which GenBank identification numbers are provided (sixth column). cThe complete coding sequence 
of each NAT gene was amplified for cloning, using combinations of the following primers, as indicated 
(seventh column): Primer #1 (forward), GCGGCAGCCATATGGACATTGAAGCATA; Primer #2 (reverse), 
TCGAGTGCGGCCGCCTAAATAGTAAAAAATCTATCACC; Primer #3 (reverse), GTGCTCGAGTGCGG 
CCGCCTAAATAGTGAAGGATC; Primer #4 (reverse), TCGAGTGCGGCCGCCTAAATAGTAAGGG 
ATCCATC; Primer #5 (reverse), TCGAGTGCGGCCGCCTAAATAGTAAAGAATCCATC. The recognition 
sites for restriction endonucleases NdeI (forward primer) and NotI (reverse primers) are underlined. Clones 
for the NAT2 genes of M. mulatta and H. sapiens were available in our laboratories from previous studies61. 
The NAT1 constructs of C. tantalus and E. patas were generated from the NAT1 construct of C. diana via 
site-directed mutagenesis with Primer #6 (forward), CCATGGACTTAGGCTTAGAGGCCAT, and Primer 
#7 (reverse), ATGGCCTCTAAGCCTAAGTCCATGG (in bold, the mutagenised nucleotide representing 
the only non-synonymous SNP differentiating the NAT1 gene of C. diana from the other two homologues). 
Amplification of the NAT2 genes of A. nigroviridis (GenBank ID: KU640981) and S. apella (GeneBank ID: 
KU640976) was not possible due to limited availability of genomic DNA.
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in human and other apes. This similarity, further supports the utility of (NOMGA)NAT1 and (NOMGA)NAT2 as 
in vitro models of the more poorly expressed human NATs.
The non-selective substrate PANS was efficient with both the NAT1 and the NAT2 isoenzymes of non-human 
primates (Fig. 2). The (MACMU/MACSY)NAT1 homologue of the two macaque species generated excessive 
activities with both PANS and PABA, which were at least 8-fold higher than the activities measured for all other 
NAT1 homologues (Fig. 2a). Similarly, (ERYPA)NAT2 was the most active NAT2 isoenzyme with PANS and its 
selective substrates PA and INH (Fig. 2b).
The highly active (MACMU/MACSY)NAT1 and (ERYPA)NAT2 homologues were further used to test 
selectivity against a series of additional NAT substrates, namely the toxic arylamines 2-aminophenol (2AP), 
4-chloroaniline (CLA), 3,4-dichloroaniline (3,4DCA) and 4-phenoxyaniline (POA), and the pharmaceutical aryl-
hydrazine hydralazine (HDZ)35. Both NAT homologues provided activity with all five substrates, but the activities 
measured with (ERYPA)NAT2 were substantially higher (>10,000 nmol/min/mg) compared with those measured 
Figure 1. Recombinant NAT proteins of primates. The NAT proteins of Homo sapiens (HUMAN), Allenopithecus 
nigroviridis (ALLNI), Cercopithecus diana (CERDI), Chlorocebus tantalus (CHLTN), Erythrocebus patas (ERYPA), 
Macaca mulatta (MACMU), Macaca sylvanus (MACSY), Mandrillus sphinx (MANSP), Nomascus gabriellae 
(NOMGA), Sapajus apella (SAPAP) and Trachypithecus cristatus (TRACR) were expressed in E. coli and isolated 
by affinity chromatography. C. tantalus and E. patas have identical NAT1 amino acid sequences, thus only one 
recombinant protein was expressed, designated (CHLTN/ERYPA)NAT1. This was also the case for the identical 
NAT1 proteins of M. mulatta and M. sylvanus, expressed as (MACMU/MACSY)NAT1. SDS-PAGE gels are shown 
with chromatographic fractions eluted with a concentration gradient of up to 250 mM of imidazole, indicated 
by shaded triangles at the top of each image. Each lane was loaded with 30 μl of eluate. The symbols in the first 
image are whole cell lysate without IPTG induction (□), whole cell lysate after IPTG induction (■), soluble cell 
extract before the affinity chromatography (○), and initial flowthrough of soluble cell extract through the affinity 
chromatography column (●). The small black arrowheads indicate bands of recombinant NAT proteins, the 
molecular weight of which (~31 kDa) was estimated relative to protein markers (lanes M). Full-length gels are 
presented in Expanded Data Supplementary Fig. 1 at the end of the Supplementary Information file.
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with (MACMU/MACSY)NAT1 (<3500 nmol/min/mg) (Fig. 3). The results suggest that 2AP, CLA, 3,4DCA, POA, 
and HDZ are more NAT2 selective, particularly taking into account that (MACMU/MACSY)NAT1 was about 
4.5-fold more active than (ERYPA)NAT2 with the non-selective substrate PANS (Fig. 2). The pattern agrees with 
previous investigations with human NATs, generated in low yields detectable by Western blot35.
Previous studies have demonstrated that NATs can utilise acyl-group donor substrates other than 
acetyl-CoA10,35,48. We thus tested (MACMU/MACSY)NAT1 and (ERYPA)NAT2 with acetyl-, n-propionyl-, 
malonyl-, succinyl- and hexanoyl-CoA as donor substrates. As demonstrated (Fig. 4), (MACMU/MACSY)
NAT1 provided activities with all five acyl-CoA compounds, in the following declining order: acetyl-CoA 
(100%) > n-propionyl-CoA (50%) > malonyl-CoA (25%) > succinyl-CoA (15%) and hexanoyl-CoA (8%). 
Activities with these compounds have also been reported with hamster NAT2 recombinant protein, which is 
functionally equivalent to human NAT135. The (ERYPA)NAT2 protein demonstrated more restricted acyl-CoA 
selectivity, utilising acetyl-CoA (100%) and n-propionyl-CoA (88%), but providing only marginal (<3%) activ-
ities with the remaining three acyl-CoA substrates tested. This pattern is more similar to that observed with 
certain microbial NATs, which are effective utilisers of acetyl- and n-propionyl-CoA, but show virtually no pref-
erence for other acyl-CoA compounds10,48.
Thermal stability of primate NAT proteins. Differential Scanning Fluorimetry (DSF) is widely employed 
as a quick, sensitive, low-cost, high-throughput technique for initial screens of pharmaceutical targets against 
candidate inhibitors or other ligands49,50. We found that application of the technique with (HUMAN)NAT1 and 
(HUMAN)NAT2 is complicated by the poor quality of recombinant protein preparations generated with our 
expression/purification scheme, which is commonly used by many laboratories. In contrast, DSF was success-
ful with the recombinant NAT proteins of non-human primates, allowing accurate assessment of their thermal 
stability with or without substrates (Figs 5 and S6). The use of recombinant NATs from non-human primates 
would, therefore, facilitate initial DSF-based screens of chemical libraries for identification of leads that may be 
further evaluated as potential inhibitors of the human homologues. For example, the gibbon (NOMGA)NAT1 
and (NOMGA)NAT2 isoenzymes appeared quite robust in DSF assays, providing Tm values of 46.34 ± 0.11 and 
51.42 ± 0.15 °C, respectively. As mentioned above, the gibbon NAT proteins are highly similar in amino acid 
sequence with their human homologues (Supplementary Table S2) and they are readily expressed and purified in 
recombinant form (Supplementary Fig. S4). Both (NOMGA)NAT isoenzymes provided Tm values in the higher 
range (Fig. 5), generating optimal DSF curves. The recombinant NAT homologues of the gibbon are, therefore, 
proposed as appropriate models of human NATs in DSF-based screens for candidate pharmaceutical compounds.
The determined Tm values for NAT homologues of non-human primates ranged from 34.01 ± 1.34 to 
46.34 ± 0.11 °C (mean value 40.07 ± 3.78 °C) for NAT1, and from 47.18 ± 0.4 to 53.23 ± 1.77 °C (mean value 
50.45 ± 2.12 °C) for NAT2, supporting that the NAT2 homologues are considerably more resilient to thermal 
denaturation than the NAT1 homologues, as has been reported previously for the human NAT isoenzymes31. 
Among NAT1 proteins, (NOMGA)NAT1 and (TRACR)NAT1 had the highest and lowest Tm values, respectively, 
translating into a difference of about 12 °C (Fig. 5a and c). Variability in Tm was more restricted among NAT2 
Figure 2. Enzyme activity screens of primate NAT homologues. Overview of the specific activities measured 
with the recombinant NAT1 (a) and NAT2 (b) isoenzymes of primate species Allenopithecus nigroviridis 
(ALLNI), Cercopithecus diana (CERDI), Chlorocebus tantalus (CHLTN), Erythrocebus patas (ERYPA), 
Macaca mulatta (MACMU), Macaca sylvanus (MACSY), Mandrillus sphinx (MANSP), Nomascus gabriellae 
(NOMGA), Sapajus apella (SAPAP), Trachypithecus cristatus (TRACR) and Homo sapiens (HUMAN). Assays 
were performed with acetyl-CoA as acyl-group donor substrate and a series of acceptor substrates, namely p-
anisidine (PANS), p-aminobenzoate (PABA), 5-aminosalicylate (5AS), procainamide (PA) and isoniazid (INH). 
Enzyme activity was detected with all NAT homologues, but varied considerably per protein and substrate used. 
Assays were performed in duplicate and variability between replicates was within 10% from the average specific 
activity shown. A presentation of enzyme activity data is provided in Expanded Data Supplementary Fig. 2 at 
the end of the Supplementary Information file.
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proteins (maximum difference of about 6 °C), with (MACSY)NAT2 and (MACMU)NAT2 providing the highest 
and lowest Tm values, respectively (Fig. 5b and d). This is noteworthy, since those two proteins are 99.31% identi-
cal and belong to species of the same genus (Supplementary Fig. S2 and Supplementary Table S2).
Other comparative aspects of primate NAT1 homologues. Human NAT1 has been the focus of 
investigations seeking to unravel its postulated role in endogenous metabolism and disease, particularly can-
cer51–53. Human NAT1 and its murine homologue have been implicated in folate metabolism via the acetylation 
of p-aminobenzoylglutamate (pABGlu)51, although recent studies suggest a more complex association between 
folate and NAT40,54,55. We show here that NAT1 is capable of pABGlu acetylation in non-human primates too, as 
expected (Supplementary Fig. S7).
Moreover, human NAT1 has been investigated as a candidate target for small-molecule inhibition56. A naph-
thoquinone inhibitor developed for (HUMAN)NAT146, also inhibited (MACMU/MACSY)NAT1 at 10 μM 
Figure 3. Additional acceptor substrate preferences of primate NAT1 and NAT2 homologues. The arylamines 
4-phenoxyaniline (POA), 2-aminophenol (2AP), 4-chloroaniline (CLA) and 3,4-dichloroaniline (3,4DCA), 
and the arylhydrazine hydralazine (HDZ) were used in assays with either (MACMU/MACSY)NAT1 of the 
two macaques or (ERYPA)NAT2 of Erythrocebus patas. These were the recombinant NAT proteins providing 
highest activities in the screens of Fig. 2. In the plot, the light grey bars are the specific activities of (ERYPA)
NAT2 with each one of the five substrates tested, also provided as percentages (%) relative to the specific activity 
measured with POA (100%). The dark grey bars are the specific activities of (MACMU/MACSY)NAT1, and 
each measurement is also provided relative (%) to the corresponding specific activity of (ERYPA)NAT2 per 
each substrate tested. Assays were performed in duplicate and variability between replicates was within 10% 
from the average specific activity shown. A presentation of enzyme activity data is provided in Expanded Data 
Supplementary Fig. 2 at the end of the Supplementary Information file.
Figure 4. Donor substrate preferences of primate NAT1 and NAT2 homologues. Two parallel sets of assays 
were performed with acetyl-, n-propionyl-, malonyl-, succinyl- or hexanoyl-CoA as donor substrates. The first 
set employed (MACMU/MACSY)NAT1 protein with p-aminobenzoate (PABA) as acceptor substrate, while 
the second utilised (ERYPA)NAT2 protein with p-anisidine (PANS). On the graph, the bars of each series are 
the relative specific activities measured with each one of the five acyl-group donor substrates tested, presented 
as percentage (%) of the corresponding specific activity measured with acetyl-CoA (100%). Assays were 
performed in triplicate and variability between replicates was within 10% from the calculated average specific 
activity. A presentation of enzyme activity data is provided in Expanded Data Supplementary Fig. 2 at the end of 
the Supplementary Information file.
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concentration (Fig. 6a). However, inhibition was lower (50% decrease in enzyme activity with PABA) for 
(MACMU/MACSY)NAT1, compared with the reported 92% with 5AS for (HUMAN)NAT146. Our enzymatic 
assays (Fig. 2a) show that (MACMU/MACSY)NAT1 is much more active than (HUMAN)NAT1, indicating that 
full inhibition would likely require a higher concentration of the naphthoquinone in the reaction. The in silico 
docking of the inhibitor to the modelled structure of (MACMU/MACSY)NAT1 protein indicated only a minor 
shift to the expected positioning within the active site. Docking of the inhibitor was the same between (HUMAN)
NAT1 and the modelled structure of (NOMGA)NAT1 (Fig. 6b,c). The limited availability of the compound at the 
time of this study precluded more sophisticated assays using a concentration range of the inhibitor with NAT1 
proteins from different non-human primates. Since those efficiently expressed homologues may constitute a use-
ful resource for future high-throughput chemical screens, further optimisation of inhibition assays is warranted. 
DSF would also be useful as a more affordable high-throughput method to screen for NAT inhibitors.
Structure-function comparisons of primate NAT proteins. The comparative approach undertaken in 
this study places the phylogeny of primate NAT homologues in the context of enzymatic function. The evolution 
of NAT enzymes has presumably been influenced by xenobiotic challenges conferred by the various habitats 
of primate species, particularly their diet. Although primate NAT proteins are highly conserved in amino acid 
sequence, they differ considerably in enzymatic activity (Fig. 2). Associating genetic variability with enzymatic 
function allows the identification of amino acid residues that may have been influenced by environmental factors 
during primate NAT evolution. Such comparisons may also reveal apparently subtle differences between NAT 
homologues that may still have a significant phenotypic impact, further advancing our knowledge of NAT cata-
lytic mechanism. This approach is focusing only on functional variability developed through the slow action of 
natural selection, so it is complementary to artificial mutagenesis of recombinant proteins which usually aims to 
alter specific residues with presupposed functional consequences31,57–59. To this end, some interesting compari-
sons are discussed below.
(MACMU/MACSY)NAT1 vs. (MANSP)NAT1. As mentioned above, the macaque (MACMU/MACSY)NAT1 
was demonstrated to be considerably more active compared with other primate NAT1 homologues (Fig. 2a). It 
shares highest phylogenetic and primary sequence similarity (98.63%) with (MANSP)NAT1 which, however, 
Figure 5. Thermal stability of primate NAT proteins. Overview of Tm values determined by DSF analysis of 
recombinant NAT1 (a) and NAT2 (b) homologues of non-human primates Allenopithecus nigroviridis (ALLNI), 
Cercopithecus diana (CERDI), Chlorocebus tantalus (CHLTN), Erythrocebus patas (ERYPA), Macaca mulatta 
(MACMU), Macaca sylvanus (MACSY), Mandrillus sphinx (MANSP), Nomascus gabriellae (NOMGA), Sapajus 
apella (SAPAP) and Trachypithecus cristatus (TRACR). The difference of each NAT1 (c) or NAT2 (d) Tm value 
from the corresponding calculated mean temperature is also plotted (the x-axis of graphs c and d corresponds 
to mean values of 40.07 °C and 50.45 °C for NAT1 and NAT2 proteins, respectively). Duplicate experiments 
were performed generating sigmoid curves that were fitted to the Boltzmann equation (Adj. R2 ≥ 0.99). The 
screens were typically repeated multiple times with different protein preparations (particularly for low-Tm NAT 
homologues), in order to ensure accuracy and reproducibility of results.
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provided 55-fold lower specific activity with the selective substrate PABA. Both proteins were very effective dur-
ing recombinant expression/purification (Fig. 1) and (MANSP)NAT1 had a higher Tm by 3.4 °C (Fig. 5a and c). 
Therefore, inherent instability of (MANSP)NAT1 protein is unlikely to explain its lower enzymatic activity rel-
ative to (MACMU/MACSY)NAT1. At the primary sequence level, the two homologues vary only at amino acid 
positions 29, 95, 273 and 280 (Supplementary Fig. S2). (MACMU/MACSY)NAT1 was the only NAT1 homologue 
in the study with glutamate at position 29, instead of glutamine. It was also the only NAT1 homologue with aspar-
agine, instead of serine, at position 95. Conversely, (MANSP)NAT1 was the only homologue with valine, instead 
of isoleucine, at position 273. Position 280 is less conserved among the compared NAT1 sequences, bearing a 
methionine in (MACMU/MACSY)NAT1, an isoleucine in (MANSP)NAT1 and a valine or methionine in other 
primates.
Variant residue 29 is located at the α2-helix, on the surface of the protein molecule and away from the active 
site. In contrast, residue 95 is positioned within the catalytic pocket, next to the highly conserved Val93 which 
has been identified as one of the key hydrophobic residues involved in binding of NAT1 selective substrates23 
(Fig. 7a). More sophisticated structure-function investigations may reveal if the bulkier Asn95 of (MACMU/
MACSY)NAT1 might confer increased enzymatic activity, relative to (MANSP)NAT1 and other primate homo-
logues with serine at this position. Residues 273 and 280, on the other hand, are unlikely to directly interact with 
the active site, although they are located at the beginning of the carboxy-terminal tail, which in human NATs is 
folding into the catalytic pocket where it interacts with CoA23.
(ERYPA)NAT2 vs. (CERDI)NAT2 and (CHLTN)NAT2. Among the primate NAT2 homologues examined, 
(ERYPA)NAT2 combined highest enzymatic activity with increased thermal stability (Figs 2b and 5b,d). It shares 
99.66% and 99.31% primary sequence identity with its phylogenetically closest homologues (CERDI)NAT2 and 
(CHLTN)NAT2, respectively. Compared with other NAT2 homologues, those three proteins demonstrated robust 
recombinant expression and purification (Fig. 1). (ERYPA)NAT2 and (CERDI)NAT2 produced comparable lev-
els of enzymatic activity which were considerably higher (10- to 20-fold with PANS) relative to (CHLTN)NAT2 
(Fig. 2b). The latter protein also had the lowest Tm of the three, suggesting decreased stability (Fig. 5b and d).
(ERYPA)NAT2 differs from (CERDI)NAT2 only at amino acid position 276. Unlike other NAT2 sequences 
in this study, which have a glycine at position 276, (CERDI)NAT2 has a glutamate (Supplementary Fig. S2). This 
Figure 6. Interaction of primate NAT1 homologues with a small-molecule inhibitor. A synthetic 
naphthoquinone inhibitor of (HUMAN)NAT1 and (MOUSE)NAT246 was used. (a) Inhibition of (MACMU/
MACSY)NAT1 homologue by 10 μM of the inhibitor in 5% (v/v) DMSO. Two replicate experiments were 
performed and the results are provided as average specific activity ± standard deviation. The enzymatic 
substrates used were p-aminobenzoate (PABA) and p-anisidine (PANS). (b) Overview of inhibitor binding 
to the active site of (MACMU/MACSY)NAT1 protein, modelled against the crystal structure of (HUMAN)
NAT1 (PDB ID: 2PQT). (c) Detailed view of inhibitor binding to the superimposed models of (HUMAN)
NAT1, (NOMGA)NAT1 and (MACMU/MACSY)NAT1 proteins. A slight shift in positioning of the inhibitor 
(particularly its m-xylene ring) within the active site of (MACMU/MACSY)NAT1 was observed, relative to the 
other two NAT1 homologues where binding showed complete overlap.
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residue is located in the carboxy-terminal tail of NAT2, on the surface of the protein molecule, and has no apparent 
interaction with other amino acids. This single difference between (ERYPA)NAT2 and (CERDI)NAT2 is, therefore, 
unlikely to have any significant consequence on enzymatic function, consistent with the experimental findings.
(CHLTN)NAT2 is different from (ERYPA)NAT2 by two amino acids at positions 47 and 140. (CHLTN)NAT2 
has a threonine and a glutamate, unlike other investigated NAT2 homologues which have an alanine and a glycine 
at these positions, respectively (Supplementary Fig. S2). The residue at position 47 is located behind the α-helix 
of the catalytic cysteine, and is also within spatial proximity to Asn41 and Arg64 which interact via hydrogen 
bonding to stabilise the active site23. It is possible that the bulkier polar threonine of (CHLTN)NAT2 destabilises 
this interaction, as opposed to the smaller hydrophobic alanine of (ERYPA)NAT2 and other NAT2 homologues 
(Fig. 7b). On the opposite side of the catalytic core, residue 140 is located right at the turn of an important loop 
stabilised through hydrogen bonding between Trp132, Gln133 and Gln14523. It is possible that the bulky nega-
tively charged Glu140 of (CHLTN)NAT2 decreases the stability of this loop, in contrast to the small glycine of 
(ERYPA)NAT2 and other NAT2 homologues (Fig. 7c).
Polymorphisms affecting amino acid residues 64 (NAT2*14 and NAT2*19 alleles) and 145 (NAT2*17 allele) 
have been reported for human NAT2 and they confer the slow acetylator phenotype (http://nat.mbg.duth.gr/). 
Slow acetylator variants are very common in human populations16 and this should be expected to be the norm for 
populations of other primates too. It is, therefore, possible that the low activity of certain NAT homologues in this 
study is due to slow acetylator variants present in the single individual sampled per each primate species. To date, 
only two NAT polymorphic variants have been reported in the literature for (MACMU)NAT2 and these are func-
tionally differentiated by a valine to isoleucine substitution at position 23160,61. Genotyping of a larger number of 
individuals would allow insight into NAT gene polymorphism in primates other than human.
(MACSY)NAT2 vs. (MACMU)NAT2. Another interesting observation arises from comparison of (MACSY)
NAT2 and (MACMU)NAT2 belonging to the two macaque species (genus Macaca). As discussed above, the two 
homologues have 99.31% amino acid sequence identity, but the enzymatic activity of (MACSY)NAT2 was up 
Figure 7. Examples of amino acid residues potentially differentiating the enzymatic function of highly 
homologous NAT proteins of non-human primates. (a) Detailed partial view of (MACMU/MACSY)
NAT1, showing residue 95 (circled) and other proximal amino acids of relevance. Residue 95 is predicted to 
functionally differentiate (MACMU/MACSY)NAT1 (Asn95) from its 98.63% homologous (MANSP)NAT1 
(Ser95). (b,c) Detailed partial view of (ERYPA)NAT2, showing circled residues 47 (b) and 140 (c), together 
with other proximal amino acids of relevance. Residues 47 and 140 are predicted to functionally differentiate 
(ERYPA)NAT2 (Ala47, Gly140) from its 99.31% homologous (CHLTN)NAT2 (Thr47, Glu140). (d) Detailed 
partial view of (MACMU)NAT2, showing residue 232 (circled) and other proximal amino acids of relevance. 
Residue 232 is predicted to functionally differentiate (MACMU)NAT2 (His232) from its 99.31% homologous 
(MACSY)NAT2 (Tyr232). The NAT1 and NAT2 homologues of non-human primates were modelled against the 
crystal structure of (HUMAN)NAT1 (PDB ID: 2PQT) and (HUMAN)NAT2 (PDB ID: 2PFR), respectively.
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to 3-fold higher relative to (MACMU)NAT2 (Fig. 2b). Among all investigated NAT2 proteins, (MACSY)NAT2 
provided highest and (MACMU)NAT2 lowest Tm values which were different by about 6 °C (Fig. 5b and d). 
Moreover, recombinant expression of (MACSY)NAT2 was considerably more efficient compared with (MACMU)
NAT2 (Fig. 1). The two homologues are different by only two amino acids at positions 155 and 232, where 
(MACSY)NAT2 has glutamate and tyrosine, and (MACMU)NAT2 has glutamine and histidine, respectively 
(Supplementary Fig. S2).
Among all primate NAT proteins investigated, glutamine is found at position 155 only in (MACMU)NAT2 
(Supplementary Fig. S2). However, this residue is located on the surface of the protein molecule and so it is pre-
dicted to have limited impact. Position 232, on the other hand, is located in the middle of β13-sheet, one of the 
four anti-parallel β-sheets of domain III. Sheets β12–β15 form a wall just behind loop 125–129 comprising impor-
tant amino acids that determine substrate selectivity of human NAT isoenzymes23,31. The intermediate space is 
also accessible to the tip of the carboxy-terminal tail. Residue 232 is located right next to the above-mentioned 
(MACMU)NAT2 polymorphic site p.Val231Ile, which sterically interacts with loop 125–12961. Although the side 
chain of residue 232 is oriented to the opposite direction from loop 125–129, it is possible that the size and polar-
ity of amino acid 232 may influence the structural integrity of β13-sheet, with impact on loop 125–129 and the 
carboxy-terminal chain (Fig. 7d).
Conclusions
This study undertook comparative functional investigation of NAT homologues from 10 non-human primates, 
in order to characterise their properties and evaluate their suitability as models of human NATs, particularly for 
in vitro screens requiring large quantities of pure recombinant protein. Considering factors, such as the overall 
amount of expressed recombinant protein, the enzymatic activity, the thermal stability and the percent iden-
tity to human NATs, certain homologues are proposed as more appropriate, i.e. (MACMU/MACSY)NAT1 and 
(ERYPA)NAT2, as well as the two NAT homologues of the gibbon N. gabriellae which show higher homology 
to human NATs. The practicality of using such homologues (instead of hard-to-express human NAT proteins) 
for standard in vitro screens lies in that the NAT proteins of non-human primates demonstrate higher sequence 
identity to human NATs (compared with previously used rodent homologues), and in that recombinant protein 
production is readily achievable once the NAT genes of non-human primates have been amplified and cloned 
from tiny amounts of genomic DNA. However, currently available rodent models for NAT20 should remain rel-
evant, if suitable compounds become validated as candidates for in vivo preclinical tests in the future. Moreover, 
the comparative investigation of NAT genes and their enzyme products in non-human primates allows better 
understanding of their role in xenobiotic metabolism and facilitates the identification of functional residues that 
may have been subject to evolutionary pressures. To that end, genotyping of multiple individuals from different 
non-human primate species may help identify genetic variability similar to that observed for NAT1 and NAT2 
genes in human populations.
Methods
Generation of gene constructs. Polymerase chain reaction (PCR) was performed with Pfu-DNA pol-
ymerase, using 10 ng of genomic DNA template. Primers (VBC Biotech) incorporating restriction sites at the 
ends of each PCR product were used according to the scheme of Table 1, and the primer annealing temper-
ature was 56 °C. Subsequent restriction cloning into the pET28b(+) plasmid was carried out as described61. 
When necessary, site-directed mutagenesis was performed with the QuikChange II kit (Agilent) and appropriate 
mutagenic primers. The insert of each construct was sequenced (GATC Biotech) with vector-specific primers 
to verify in-frame translation into the expected N-terminal hexa-histidine tagged NAT amino acid sequence. 
Computational analyses of sequences (e.g. alignments, calculation of percent identities and phylogeny) were car-
ried out with BioEdit Sequence Alignment Editor and MEGA62. All NAT gene constructs were maintained as 
clones in E. coli strain BL21(DE3)pLysS (Promega).
Expression and chromatographic purification of recombinant proteins. Expression of recombinant 
proteins was performed in 250 ml of Terrific Broth medium with 50 μg/ml kanamycin, during overnight incubation 
at 15 °C (120 rpm), after induction with 1 mM isopropyl-1-thio-D-galactopyranoside (IPTG) at culture optical 
density (600 nm) of approximately 1. Soluble fractions of bacterial lysates were recovered in 20 mM Tris-HCl (pH 
7.5), 500 mM NaCl, 0.1% (w/v) 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 5 mM 
imidazole, 5% (v/v) glycerol, 2 mM β-mercaptoethanol and a commercial cocktail of protease inhibitors. Affinity 
chromatography took place through Ni-NTA resin (Qiagen) and recombinant proteins were eluted with increasing 
amounts of imidazole (25, 50, 100 and 250 mM). Procedures were performed as described10.
For proteins further purified by ion exchange and gel filtration chromatography, recombinant expression took 
place in 500 ml cultures and affinity chromatography followed according to the procedures above. Ion exchange 
chromatography was performed with an ÄKTA Purifier Core System carrying a positively charged Mono Q 5/50 
GL column (GE Healthcare). This column was appropriate, as the isoelectric point (pI) of NAT proteins was cal-
culated to range between 5 and 6, and the protein molecules were thus expected to be negatively charged in the 
chromatographic buffer used (pH 7.4). A concentration gradient (50 mM to 1 M) of NaCl was achieved by gradual 
mixing of buffer A (20 mM Tris-HCl pH 7.4, 50 mM ɛ-aminocaproic acid, 5 mM EDTA) with buffer B (buffer A 
plus 1 M NaCl), and the procedure was monitored by measuring absorbance at 280 nm.
Gel filtration chromatography was performed using a Superdex 75 10/300 GL column attached to the ÄKTA 
Purifier Core System (GE Healthcare). The expected molecular weight of mammalian NAT proteins is 30–35 kDa. 
Protein separation took place in buffer containing 20 mM Tris-HCl (pH 7.5), 300 mM NaCl, and the proce-
dure was monitored at 280 nm. Molecular weight standards (Sigma-Aldrich) comprised proteins (0.5 mg each) 
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bovine serum albumin (66.8 kDa), ovalbumin (44.3 kDa), soybean trypsin inhibitor (21.5 kDa) and bovine heart 
cytochrome c (12.4 kDa), which were eluted at volumes of 3.5, 4.5, 6 and 7 ml, respectively.
Buffer change of protein preparations was performed between different chromatographic procedures 
by overnight (4 °C) dialysis through 10 kDa molecular weight cut-off pore size membrane (Sigma-Aldrich). 
Concentration of protein solutions was carried out by centrifugation (4 °C) through filter devices (Ultracel 
YM-3, Microcon) with molecular weight cut-off pore size of 3 kDa. Removal of the N-terminal hexa-histidine 
tag of recombinant proteins was achieved via overnight (4 °C) cleavage by 1 U of human plasma thrombin 
(Sigma-Aldrich) per milligram of protein in 20 mM Tris-HCl (pH 7.5), 300 mM NaCl. Protein concentration 
was determined spectrophotometrically at 280 nm, and preparations were inspected by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) after each purification process. Yields of incompletely purified 
recombinant proteins were estimated by densitometric analysis of gels, as described61.
Enzyme activity and inhibition assays. The colorimetric method with Ellman’s reagent (5,5′-dithiobis- 
2-nitrobenzoic acid) was used to measure NAT enzyme activity of recombinant proteins63, following our standard-
ised in-house protocol10,61. Replicate reactions were performed with acetyl-CoA (CID: 444493), n-propionyl-CoA 
(CID: 92753), malonyl-CoA (CID: 644066), succinyl-CoA (CID: 92133) or hexanoyl-CoA (CID: 449118) as donor 
substrates, and 2-aminophenol (2AP; CID: 5801), 4-chloroaniline (CLA; CID: 7812), p-anisidine (PANS; CID: 7732), 
4-phenoxyaniline (POA; CID: 8764), p-aminobenzoate (PABA; CID: 4876), 5-aminosalicylate (5AS; CID: 4075), 
3,4-dichloroaniline (3,4DCA; CID: 7257), procainamide (PA; CID: 4913), p-aminobenzoylglutamate (pABGlu; 
CID: 196473), isoniazid (INH; CID: 3767) or hydralazine (HDZ; CID: 3637) as acceptor substrates. The amount of 
dimethylsulphoxide (DMSO) per reaction was 0.5% (v/v). All compounds were from Sigma-Aldrich.
Inhibition assays with a previously characterised human NAT1 selective naphthoquinone inhibitor46 were 
carried out using 1 μg of affinity chromatography purified recombinant NAT1 protein mixed with 10 μM of inhib-
itor in 20 mM Tris-HCl (pH 7.5), 5% (v/v) DMSO, prior to addition of 0.5 mM of substrate (PANS or PABA). 
Reactions were initiated with 0.5 mM acetyl-CoA and stopped after 30 s for colorimetric measurement of released 
CoA. Control reactions with 5% (v/v) DMSO but no inhibitor were also performed.
Differential scanning fluorimetry. Differential scanning fluorimetry (DSF) was performed exactly as 
described10,61 to determine the denaturation midpoint temperatures (Tm) of different NAT proteins, as well as to 
examine the effects of compound binding.
Molecular modelling of protein structures. The published crystal structures23 of human NAT1 (PDB 
ID: 2PQT) and NAT2 (PDB ID: 2PFR) proteins were used to model the secondary and tertiary structures of NAT 
homologues from other primates. Alignments of non-human NATs to the secondary structure of human NATs 
were performed with T-COFFEE Expresso (http://tcoffee.crg.cat/apps/tcoffee/do:expresso)64 and graphically 
visualised with ESPript3.0 (http://espript.ibcp.fr)65. The tertiary structure of non-human NATs was modelled 
to the three-dimensional structure of human NATs using SWISS-MODEL (http://swissmodel.expasy.org/) and 
graphically visualised on PyMOL (Schrödinger, LLC). Docking analysis was performed as described39. In the 
available structure of human NAT1, the catalytic Cys68 appears modified as S-(2-anilino-2-oxoethyl)-L-cysteine 
and this modification was removed to restore the functional residue.
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